FDA’s final guidance on nonproprietary naming gives biosimilar developers and innovative biologic product sponsors more clarity on how four-letter suffixes will be evaluated for distinguishable nonproprietary names, but it also leaves a wake of questions about how the agency will implement this policy across a large swath of approved products.
The agency is sticking with its plan to require that distinguishable suffixes devoid of meaning be added to the nonproprietary...